Across TCGA pan-cancer cohorts, CACNG4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CACNG4 data layer compared with 29 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CACNG4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CACNG4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.
SKCM, LUSC, and UCEC are the cancer types where CACNG4 Mutation most reproducibly stratifies survival.